Abstract
AUTO3, the first chimeric antigen receptor (CAR) T‐cell therapy targeting both CD19 and CD22, shows promise in combination with pembrolizumab in patients with relapsed/refractory diffuse large B‐cell lymphoma, according to results from a phase I trial.